Related Experiment Video
Updated: Dec 13, 2025
Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
Published on: October 13, 2023
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and
Ana Oaknin1, Alicia León-Castillo2, Domenica Lorusso3
1Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Purpose Of Review:
Changes in molecular classification together with a deeper knowledge of both immune disregulation and phosphatidylinositol-3 kinase (PI3K) pathway alterations are leading to a new endometrial cancer treatment paradigm. This review will address the cutting-edge data in this field.
Recent Findings:
This article will cover the updated data in endometrial cancer molecular classification and its correlation with the outcomes in randomized clinical trials (e.g., PORTEC-3). Moreover, we will review the latest data regarding checkpoint blockade molecules (CPB) in the recurrent setting and how they are changing the treatment landscape. In addition, the role of the PI3K inhibitors, their activity, and toxicity profile will be described.
Summary:
As result of the incorporation of molecular classification in our daily practice, the adjuvant treatment in endometrial cancer is rapidly evolving and leading to a new paradigm. The promising data observed with CPB in the recurrent setting have led to the food and drug administration approval of pembrolizumab as monotherapy and in combination with lenvatinib. Additionally, the current outcomes achieved with PI3K inhibitor agents encourage us to continue our clinical research to identify those patients who may benefit the most.
Insights
Endometrial cancer treatment is evolving with molecular classification, immune checkpoint blockade, and PI3K inhibitors. These advances are creating new therapeutic paradigms for improved patient outcomes.
Area of Science:
- Gynecologic Oncology
- Molecular Oncology
- Immunotherapy
Background:
- Endometrial cancer treatment is shifting due to molecular insights.
- Understanding immune dysregulation and PI3K pathway is crucial.
Purpose of the Study:
- Review cutting-edge data in endometrial cancer treatment.
- Discuss molecular classification, immune checkpoint blockade, and PI3K inhibitors.
Main Methods:
- Literature review of recent randomized clinical trials.
- Analysis of data on checkpoint blockade molecules (CPB) and PI3K inhibitors.
Main Results:
- Molecular classification impacts adjuvant treatment strategies.
- CPB, like pembrolizumab, shows promise in recurrent endometrial cancer.
- PI3K inhibitors demonstrate activity and are under continued investigation.
Conclusions:
- Molecular classification is reshaping endometrial cancer care.
- CPB and PI3K inhibitors represent a new treatment paradigm.
- Further research is needed to personalize therapy with these agents.
More Related Videos
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...